Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Net Income
(117,042)
(630,210)
(171,799)
(133,969)
Operating Activities, Cash Flows Provided By or Used In
Depreciation
--
96,912
47,187
56,744
Changes In Accounts Receivables
--
(51,483)
(16,367)
(26,650)
Changes In Assets and Liabilities
--
(160,276)
46,332
(30,340)
Changes In Inventories
--
(64,512)
(50,989)
(36,847)
Changes In Other Operating Activities
117,042
581,732
(76,053)
97,523
Total Cash Flow From Operating Activities
--
(227,837)
(221,689)
(73,539)
Investing Activities, Cash Flows Provided By or Used In
Capital Expenditures
(159,329)
(148,380)
(227,653)
(118,834)
Investments
--
(332,180)
(451,797)
247,889
Other Cash flows from Investing Activities
159,329
(3,487)
(500,148)
65,500
Total Cash Flows From Investing Activities
--
(484,047)
(1,179,598)
194,555
Financing Activities, Cash Flows Provided By or Used In
Dividends Paid
--
--
--
--
Sale/Purchase of Stock
--
712,938
888,257
117,464
Net Borrowings
--
--
--
0
Other Cash Flows from Financing Activities
--
14,170
39,656
68,225
Total Cash Flows From Financing Activities
--
727,108
927,913
185,689
Effect Of Exchange Rate Changes
--
(3,934)
(5,072)
(3,398)
Change In Cash and Cash Equivalents
--
11,290
(478,446)
306,705

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information